Complex Regional Pain Syndrome: A Scholarly Review by O\u27Brien, Joseph
Butler Journal of Undergraduate Research 
Volume 7 
2021 
Complex Regional Pain Syndrome: A Scholarly Review 
Joseph O'Brien 
University of Rhode Island 
Follow this and additional works at: https://digitalcommons.butler.edu/bjur 
Recommended Citation 
O'Brien, Joseph (2021) "Complex Regional Pain Syndrome: A Scholarly Review," Butler Journal of 
Undergraduate Research: Vol. 7 , Article 17. 
Retrieved from: https://digitalcommons.butler.edu/bjur/vol7/iss1/17 
This Article is brought to you for free and open access by the Undergraduate Scholarship at Digital Commons @ 
Butler University. It has been accepted for inclusion in Butler Journal of Undergraduate Research by an authorized 
editor of Digital Commons @ Butler University. For more information, please contact digitalscholarship@butler.edu. 
BUTLER JOURNAL OF UNDERGRADUATE RESEARCH, VOLUME 7 
 
 250 
COMPLEX REGIONAL PAIN SYNDROME: A SCHOLARLY 
REVIEW  
 
JOSEPH O'BRIEN, UNIVERSITY OF RHODE ISLAND 
MENTOR: GUY W. FRIED 
 
Abstract 
Complex regional pain syndrome (CRPS) is a mystifying, often disabling, 
neurogenic pain disorder affecting millions of individuals. Although this condition 
was described in medical literature as early as 1864, CRPS remains controversial, 
often misunderstood, and frequently incorrectly diagnosed and treated. Patients 
afflicted with CRPS often suffer unnecessarily because of these factors. This paper 
reviews the history of CRPS, the evolution of its diagnosis and treatment, and the 
leading theories on its pathogenesis. This paper also includes case studies of two 
female patients currently suffering from CRPS. Their stories demonstrate some of 
the unique challenges confronting CRPS patients, including medical, financial, and 
health insurance issues. 
Complex regional pain syndrome (CRPS) is a life-altering, mystifying 
neurologic pain condition that arises from a traumatic insult to an extremity or 
peripheral nerve (2). This condition is not widely understood by medical 
professionals. No single diagnostic tool definitively confirms a CRPS diagnosis. 
There is also no universally effective treatment for this condition (1, 2, 6). Because 
it is not fully understood, this condition can cause confusion and uncertainty among 
patients and treating physicians. Patients complaining of CRPS pain can sometimes 
be dismissed as drug-seeking (15). Signs and symptoms of CRPS frequently 
overlap with those of other chronic pain conditions, which can lead to misdiagnosis 
and underdiagnosis of CRPS (9). The lack of a single, definitive treatment for CRPS 
can lead to a long, frustrating clinical path for both patients and clinicians. Even 
when CRPS is diagnosed timely and treatment is initiated appropriately, the 
prognosis remains uncertain (28). This little-understood condition profoundly 
affects the quality of life of patients of all ages and walks of life. This review 
examines the existing medical literature regarding CRPS and also includes case 
studies on two patients currently suffering from the condition.   
 




Doctors have described signs and symptoms consistent with CRPS since the 
16th century. During the American Civil War, physician Silas Weir Mitchell 
recorded what is now thought to be the earliest careful, thorough description of 
CRPS. He described patients with complaints of severe burning pain accompanied 
by red, glossy skin (2). In his 1864 book Gunshot Wounds, and Other Injuries of 
Nerves, Mitchell first used the term causalgia for this condition, from the Greek 
words causos (heat) and algia (pain; 2). Mitchell noted that all of the patients who 
exhibited these particular signs and symptoms had suffered peripheral nerve 
injuries (4).  
The term causalgia was used as the diagnositic term for several decades for 
patients exhibiting these signs and symptoms (3). Then the term reflex sympathetic 
dystrophy (RSD) was coined by Massachusetts physician James A. Evans (4). 
Between 1946 and 1947, Evans described signs and symptoms exhibited by several 
of his patients that were very similar to those described by Mitchell (4). Evans chose 
the term reflex sympathetic dystrophy because he believed that reflexive 
abnormalities of the sympathetic nervous system, not necessarily a discrete injury 
to a peripheral nerve, caused the characteristic intense chronic pain as well as 
diaphoresis, atrophy, and red, inflamed skin (4). He noted that signs and symptoms 
characteristic of “causalgia” resulted primarily from fractures, sprains, and vascular 
complications rather than from direct insults to peripheral nerves, and he concluded 
that a different name for the condition was therefore appropriate. Thus, the term 
RSD came to largely replace the term causalgia (4).  
This condition was destined to undergo yet another name change. In 1973, 
the International Association for the Study of Pain (IASP) was founded in order to 
standardize terminology used to classify chronic pain disorders, including RSD (3). 
In 1993, the IASP organized a consensus conference in Orlando, Florida, to devise 
diagnostic criteria specifically for RSD that would serve as the “gold standard” for 
clinical diagnosis (4). Before any criteria were drafted, however, it was agreed to 
change the name from reflex sympathetic dystrophy to complex regional pain 
syndrome (3, 4). The reason for the name change was that the term reflex 
sympathetic dystrophy implied a precipitating injury to a peripheral nerve, but 
clinicians recognized that many patients with RSD had not suffered a major nerve 
injury prior to the onset of pallor, sweating, edema, and other symptoms (4). The 
Orlando conference thus adopted the terms CRPS-1 and CRPS-2. CRPS-1 replaced 
the term RSD for patients with no confirmed nerve injuries, and CRPS-2 replaced 
the term causalgia for patients with confirmed nerve injuries (4).  
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The Orlando consensus conference created the following criteria for the 
clinical diagnosis of CRPS: 
1. A noxious event or immobilization able to start the process 
2. Allodynia, hyperalgesia, or any pain out of proportion compared to the 
precipitating event 
3. Presence of edema, changes in skin blood flow, or abnormal sudomotor 
activity of the affected region in any stage of the disease process 
Notably, the diagnosis of CRPS can be excluded if the presence of this kind 
of pain and dysfunction can be related to other diseases. 
The diagnostic criteria established at the Orlando conference are still used 
today. Those diagnostic criteria were purely subjective and based only on reported 
symptoms, however, which led to high rates of misdiagnosis and false positives 
(less than 50% specificity; 3). As a result of the vague nature of the original 
diagnostic criteria put into place by the Orlando conference, some patients 
diagnosed with CRPS were in fact suffering from other medical conditions. 
Another conference was thus held, in Budapest in 2003, with the goal of creating 
new and improved diagnostic criteria and classification systems for CRPS (4), and 




These diagnostic criteria are similar in nature to those drafted at the Orlando 
conference. As the name implies, however, the Orlando consensus conference 
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criteria were entirely consensus-driven and resulted in low specificity rates (3). By 
contrast, the Budapest criteria were research-driven and provided significantly 
higher specificity rates (69%; 3). Since 2003, the revised Budapest diagnostic 
criteria for CRPS have been accepted by the IASP (3). These criteria have been 
increasingly utilized by medical professionals, as they allow for effective CRPS 
diagnosis and research (3). The result has been a reduction in the incidence of 
misdiagnosis and an increase in accurate diagnosis and initiation of timely 
treatment.  
Clinical Presentation 
CRPS can occur in any person at any age, although females are at the 
highest risk for developing the condition (6). The exact reasons for this 
phenomenon are still unknown, but studies suggest that hormonal factors may be 
to blame (6). CRPS occurs mainly in distal extremities and can be caused by a 
variety of precipitating events (1). The most common causes of CRPS-1 (no 
apparent inciting nerve injury) include minor fractures, sprains, and dislocations 
(1). The immobilization (i.e., casting) period following one of these injuries has 
also been shown to increase the likelihood of CRPS development (6). CRPS-2 
results from trauma to a peripheral nerve. Elective surgeries, myocardial infarction, 
and stroke have also been shown to cause CRPS. CRPS occurs more frequently in 
upper extremities than in lower extremities, and it typically affects only one limb 
(2). 
The most common tell-tale symptom of CRPS is severe, burning pain (1). 
This pain is constant, chronic in nature, and typically disproportionate to the 
inciting injury or event (6). According to the McGill pain index, patients with CRPS 
experience the highest-ranking, most painful form of chronic pain (worse than 
amputation of a digit or unprepared childbirth). This pain is often debilitating and 
may cause a number of secondary conditions (discussed below). According to the 
Budapest diagnostic criteria, other common signs and symptoms of CRPS include 
inflammation, allodynia, hyperalgesia, edema, hyperhidrosis, skin-temperature 
abnormalities, and trophic changes (hair, nails, or skin). Several images of these 
signs and symptoms are shown below.  
 






CRPS may progress through three distinct phases: the acute/warm phase, 
intermediate phase, and chronic/cold phase (7). The acute/warm phase is 
characterized by burning pain and localized inflammation (7). Inflammation results 
in redness and swelling of the skin, which leads to an increase in skin temperature. 
Stiffness, decreased range of joint motion, and unusual hair and/or nail growth also 
accompany this phase (6). This acute phase lasts for roughly one to three months 
following the initial onset of CRPS (6). An accurate diagnosis and proper treatment 
during this crucial initial phase result in the most favorable patient outcomes (6). 
The longer the condition goes undiagnosed and untreated, the less favorable the 
prognosis.  
The intermediate phase is defined by a reduction in inflammation and, in 
some cases, a return to normal skin temperature (7), although pain continues to 
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worsen and muscles begin to atrophy (6). This phase lasts from three to six months 
following the onset of CRPS (6). During this time, the adverse effects of CRPS can 
still be remedied or reversed by effective treatment.  
Studies have shown that a decrease in norepinephrine levels accompanies 
the acute phase of CRPS (6). The decrease in norepinephrine leads to vasodilation 
and increased skin temperature in the affected region. If the CRPS is left untreated, 
the patient’s body eventually develops increased peripheral catecholamine 
sensitivity to compensate for this physiological change (2). This causes spasms in 
the affected peripheral musculature, as well as excessive vasoconstriction (6). 
Vasoconstriction causes skin in the surrounding area to become cyanotic and cold 
to the touch, which is a characteristic sign of the chronic, or cold, phase of CRPS. 
The chronic phase of CRPS is the most severe, clinically significant, phase of the 
condition (6). During this phase, pain spreads through the entire affected limb, and 
irreversible tissue damage may occur (6). Motor impairments (e.g., reduced hand 
function) begin to arise, causing a marked decrease in overall quality of life (6). It 
is important to note that not every patient will exhibit signs and symptoms 
indicative of each of the three major phases of CRPS (6), as the phases and rate of 
progression of CRPS are variable.  
Diagnosis and Diagnostic Tools 
As stated above, the currently accepted clinical diagnostic criteria for CRPS 
are the Budapest criteria, which are shown again below. 
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For a confident diagnosis of CRPS, patients must display at least one 
symptom in three or more of the symptom categories and at least one sign in two 
or more of the sign categories. These diagnostic criteria are widely utilized by 
clinicians and serve as the current standard in CRPS diagnosis (2).  
CRPS diagnosis can be difficult and is largely exclusionary (8). This means 
that conditions comprising the common differential diagnoses of CRPS must be 
ruled out before a CRPS diagnosis can be made definitively. Some of these 
conditions include neuropathy, erythromelalgia, cellulitis, lymphedema, deep vein 
thrombosis, vasculitis, and Raynaud’s syndrome (8). Because of the overlap of 
signs and symptoms among these conditions, CRPS has been cited as one of the 
most underdiagnosed and misdiagnosed conditions in medicine (9).  
There is no single gold-standard test for definitive diagnosis of CRPS, as 
the diagnosis is largely clinical (1). Several objective tests can support the 
diagnosis, however, including triple-phase bone scan (TPBS), MRI, thermography, 
and sweat-production test (1). The TPBS is a generally accepted diagnostic tool (1); 
a TPBS performed on a patient suffering from CRPS will show certain 
characteristic abnormalities that clinicians use to confirm the clinical diagnosis of 
CRPS. The TPBS utilizes a radioactive tracer, so if a patient does have CRPS, this 
test provides clinicians with images showing increased perfusion and unequal blood 
pooling in the affected extremity (1).  
MRIs are also used by clinicians as a diagnostic tool for CRPS, as they can 
reveal a multitude of tissue abnormalities common among patients with CRPS (1). 
Some of these abnormalities include soft-tissue edema, skin thinning/thickening, 
and, in severe cases, muscle atrophy (12). According to a study by M. E. Schweitzer 
and colleagues (12), MRIs can be used to distinguish between the three common 
phases of CRPS, particularly the acute and chronic phases. The authors found that 
in 35 patients with acute-phase CRPS, 31 exhibited skin thickening. No muscular 
atrophy was observed in the acute-phase cohort, but of five patients with chronic-
phase CRPS, four exhibited muscular atrophy (12). This study by Schweitzer and 
colleagues provides evidence that MRIs can be useful in differentiating between 
distinct stages of CRPS, although conflicting evidence exists regarding the efficacy 
of MRIs in the initial clinical diagnosis of CRPS (1). 
Thermography tests are highly accurate diagnostic assessments that easily 
detect the temperature asymmetry of the skin that is seen in patients with CRPS 
(11). The findings presented in a study by Gulevich et al. and reported by Sjoerd 
Niehof and colleagues (11) show that the sensitivity and specificity of infrared 
thermography used in the diagnosis of CRPS were 93% and 89%, respectively (11). 
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Futhermore, Niehof and colleagues sought to examine the effect of alterations to 
ambient temperature on the sensitivity and specificity of thermography tests used 
to aid in the diagnosis of 12 CRPS patients (11). They found that the patients’ 
affected and unaffected extemities did not exhibit optimal obtainable temperature 
differences at room temperature but exhibited much more pronounced temperature 
differences at warm and cold ambient temperatures (11). These findings suggest 
that alterations in ambient temperature act to further improve the sensitivity and 
specificity of thermography tests in the diagnosis of CRPS.  
Along with skin-temperature abnormalities, abnormal diaphoresis 
commonly accompanies CRPS (12); sweat-production tests are thus commonly 
used to aid in the diagnosis of CRPS. These tests measure the levels of sweat on 
two limbs and may indicate a case of CRPS if the sweat levels are unequal (1). 
Pathogenesis 
The pathogenesis of CRPS is complicated and multifaceted. During the 
early phases of CRPS, exacerbation of neurogenic inflammatory mechanisms 
occurs (13). CRPS-related neurogenic inflammation occurs when Group C nerve 
fibers (essential in nociception) become continuously strained (13). Several 
neuropeptides—importantly, calcitonin gene-related peptide (CGRP)—are 
released in response to C-fiber stimulation (13). CGRP increases vasodilation while 
promoting sweat-gland activation and hair growth (13). Exacerbation of 
neuroinflammatory mechanisms with subsequent release of CGRP in patients with 
CRPS likely explains the characteristic increase in skin temperature, edema, and 
increased hair and nail growth seen in the early phases of CRPS.  
Interestingly, the use of angiotensin-converting enzyme (ACE) inhibitors 
has been shown to increase the risk for CRPS development (14). ACE acts to inhibit 
CGRP; thus, the inhibition of ACE further enhances release of CGRP and causes 
neurogenic inflammatory effects (14). A study by de Mos et al. (14) revealed that 
a high dosage and prolonged use of ACE inhibitors further increases the incidence 
of CRPS. 
Another key feature of the pathogenesis of CRPS is the onset of peripheral 
sensitization and, in some cases, central sensitization (15). In general, sensitization 
is defined as an increased responsiveness of neurons to normal input or recruitment 
of a response to subthreshold inputs (15). Sensitization arises when a continuous 
noxious stimulus, such as the chronic pain of CRPS, causes afferent neurons (and 
other nociceptive mechanisms) to exhibit heightened sensitivity over time (15). 
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This causes the brain to interpret previously nonpainful stimuli, such as light touch, 
as painful, which is indicative of primary hyperalgesia/allodynia (16). If left 
unchecked, peripheral sensitization itself can lead to central sensitization (15). 
According to a study by Latremoliere and Woolf, a noxious stimulus must be 
severe, recurrent, and sustained in order to induce central sensitization. This means 
that the abnormally high pain signals from CRPS cause peripheral sensitization, 
which in turn can lead to central nervous system (CNS) sensitization. Once the CNS 
becomes abnormally sensitized because of CRPS, a patient can experience severe 
pain in response not only to light touch but also to stimuli such as sound, light, and 
alterations in barometric pressure (15).   
Glial cells of the CNS play a major role in the onset of central sensitization 
(15). Glial cells normally function in the CNS to form myelin and to provide 
support and protection for neurons (15). These cells are normally dormant in the 
CNS, but during central sensitization, they become active and produce 
inflammatory mediators (called cytokines), which in turn cause nerve inflammation 
(15). Two of these inflammatory mediators are tumor necrosis factor alpha (TNFα) 
and interleukin-1β (IL-1β). TNFα and interleukin-1β act on the dorsal horn of the 
spinal cord, which contains cell bodies of sensory neurons (16). The action of these 
inflammatory mediators on the dorsal-horn neurons may result in secondary 
hyperalgesia, which is defined as a spread of pain hypersensitivity past the original 
point of peripheral injury (16). 
NMDA receptors—membrane-bound ion (importantly, calcium) channels 
that are numerous in the CNS and found on sensory neurons (15)—are also crucial 
in the development and maintenance of central sensitization (31). Peripheral 
sensitization and inflammation can alter the properties of these receptors and, in 
turn, the sensory neurons that they mediate (15). Typically, the calcium-channel 
gates of NMDA receptors are blocked by magnesium, but this magnesium block is 
released during the central sensitization process, resulting in a rapid influx of 
calcium ions and subsequent sensitization of neurons (31). 
Evidence suggests that people with CRPS experience certain perceptual 
abnormalities. This may be caused by a phenomenon known as brain plasticity, or 
neuroplasticity, which is the ability of the brain to “rewire” itself and its 
connections (16). This is what allows the brain to develop from infancy to 
adulthood (16). In people with CRPS, this reorganization of the nervous system 
(particularly the brain cortex) is thought to occur in response to continuous painful 
stimuli (16). Several of the perceptual abnormalities resulting from brain plasticity 
in CRPS patients include an inability to identify objects by touch without visual 
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input, finger proprioception abnormalities, abnormal body scheme, and defects in 
the mental representation of the affected limb (16). According to Kuttikat et al. 
(16), one potential cause of these perceptual disturbances is reorganization of the 
cerebral cortex. This region of the brain functions in sight, hearing, and memory as 
well as sensory and motor function; thus, cortical reorganization may disrupt 
typical somatosensory functioning and lead to the sensory and motor impairments 
noted above (16). A study by Cohen et al. (17) examined 22 patients with chronic 
CRPS-1 to assess for parietal-lobe dysfunction. They found that 15 of the 22 
patients had some form of parietal-lobe dysfunction and exhibited symptoms such 
as sensory extinction and dysynchria. They also found that increased parietal-lobe 
dysfunction was correlated with increased body-surface allodynia (17). Although 
studied extensively, the exact physiological underpinnings leading to nervous-
system reorganization in CRPS patients are still unknown. This phenomenon 
greatly affects activities of daily living and can result in lifelong somatosensory 
dysfunction (16). 
Treatment 
Although clinicians employ a multitude of treatments for CRPS, the 
efficacy of some of these has yet to be established through peer-reviewed research. 
This section addresses only those treatment options that have been reported as 
efficacious in peer-reviewed literature. In terms of pharmacological treatment, 
evidence compiled by Perez et al. (21) suggests that subanesthetic ketamine, 
gabapentin, dimethylsulphoxide (DMSO), N-acetylcysteine (NAC), and others are 
at least partially efficacious at alleviating some of the pain experienced by patients 
with CRPS. Stellate ganglion blocks, spinal cord stimulation, and surgical 
sympathectomy have also been proven to be therapeutic in relieving CRPS pain 
(18). Additionally, physical therapy and occupational therapy are effective 
noninvasive, nonpharmacological treatments for CRPS (18). 
As noted above, a number of evidence-based pharmacological treatment 
options for CRPS exist. It should be noted, however, that the scientific evidence for 
these treatments is somewhat limited (18). Ketamine infusions are commonly 
administered to people with CRPS (18). A study by Correll et al. (18) reviewed 
case notes for 33 CRPS patients who had undergone subanesthetic ketamine 
infusions for pain relief, in order to determine if ketamine was indeed effective in 
reducing pain. All 33 patients underwent ketamine infusions at least once; 12 
underwent a second course of ketamine therapy, and 2 underwent a third (19). 
Correll et al. (18) found that after the initial administration of ketamine, 25 patients 
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reported complete pain relief, 6 reported partial relief, and only 2 reported no relief. 
The degree of pain relief also appeared to increase with multiple ketamine 
infusions, as the 12 patients who underwent second and/or third infusions all 
reported complete pain relief (19). The duration of reported pain relief ranged from 
three months to three years, and the patients who had undergone more than one 
infusion reported longer durations of pain relief (19). Although ketamine has been 
shown to effectively relieve CRPS pain, it may cause significant side effects, which 
can include hallucinations, dizziness, intoxication, and nausea (18, 19).  
Gabapentin, an anticonvulsant, has also been shown to reduce neuropathic 
pain consistent with CRPS (18). An eight-week study by Serpell and the 
Neuropathic Pain Study Group (20) assessed average daily pain scores in 305 
patients with various neuropathic pain syndromes. Of these 305 patients, 153 were 
given three separate, progressively increased doses of gabapentin while 152 were 
given a placebo (20). At the culmination of the eight-week study, it was found that 
the average daily pain scores of patients treated with gabapentin improved (i.e., 
decreased) by 21% (20). These findings are promising, but the study’s sample 
cohort consisted of patients with various neuropathic pain disorders, not only those 
with CRPS; thus, more evidence is needed to determine how effective gabapentin 
is in the treatment of CRPS pain specifically (18). 
Some studies indicate that the free radical scavengers DMSO and NAC may 
be effective in treating CRPS patients (18). One study by Perez et al. (21) sampled 
146 CRPS patients and sought to compare the effects of these two free radical 
scavengers on CRPS pain. The patients were divided randomly into two groups and 
were treated for 17 weeks. One group was treated with 50% DMSO cream five 
times per day, and the other was treated with 600-mg NAC tablets three times per 
day (21). Researchers concluded that both treatments were moderately effective in 
reducing CRPS pain. Interestingly, 50% DMSO cream was more therapeutic for 
patients with acute/warm-phase CRPS, and the 600-mg NAC tablets were more 
therapeutic for patients with cold-phase CRPS (21). 
Treatment of CRPS with stellate ganglion blocks is widely utilized by 
medical professionals (15), and studies support the efficacy of stellate ganglion 
block therapy. One study, by Yucel et al. (22), included 22 patients with CRPS-1 
who had suffered either distal radial fractures or soft-tissue hand traumas or had 
undergone surgery for carpal tunnel syndrome. All patients received three total 
stellate ganglion blocks, with one week in between each injection, and a 0–10 pain 
scale was used to evaluate each of the patients before treatment and two weeks after 
treatment (22). Wrist-joint range of movement (ROM) was also assessed before and 
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after treatment (22). Stellate blocks were found to significantly improve both CRPS 
pain and joint ROM in all patients (22). Overall wrist flexion improved from 50.2 
± 13.8 degrees to 69.4 ± 8.1 degrees; overall wrist extension improved from 38.9 ± 
12.8 degrees to 58.7 ± 7.8 degrees; and overall supination improved from 41.1 ± 
11.6 degrees to 63.1 ± 8.0 degrees (22). Blocks significantly improved pain in all 
patients as well (p < 0.05; 22). The study by Yucel et al. indicates that stellate 
ganglion blocks do indeed alleviate CRPS-related pain and improve joint ROM.   
Spinal cord stimulation has been shown to reduce pain in individuals with 
chronic CRPS (18, 23). In a study by Kemler et al. (23), 36 patients with chronic 
CRPS were divided into two treatment groups, one receiving spinal cord 
stimulation with physical therapy and the other receiving physical therapy alone. 
Pain levels were assessed using a visual analog scale, with 0 cm being the lowest 
level of pain and 10 cm being the highest (23). The researchers found that after six 
months, patients who received spinal cord stimulation with physical therapy 
exhibited a mean reduction of 2.4 cm on the visual analog pain scale, whereas 
patients participating in physical therapy alone exhibited a mean reduction of only 
0.2 cm (23). Although spinal cord stimulation significantly reduced pain in chronic 
CRPS patients, no improvement of functional capacity was noted (18, 23). There is 
also no evidence of pain reduction due to spinal cord stimulation for patients with 
non-chronic CRPS (18). It therefore appears that spinal cord stimulation is effective 
in reducing the subjective pain levels of patients with chronic CRPS, though it has 
not been shown to increase their level of function.   
Surgical sympathectomy, in which a portion of the sympathetic nerve chain 
is severed in order to prevent nerve signals from passing into a specific area (i.e., 
the affected limb in CRPS), has been shown to relieve pain in patients with CRPS 
(18, 24). A study by Duarte et al. (25) sought to examine the effects of endoscopic 
thoracic sympathectomy (ETS) on pain levels of seven patients with CRPS. An 
ETS was performed on each of the seven patients, and subsequent pain levels were 
measured using the 0–10 visual analog scale (25). In all seven patients, resting pain 
completely disappeared following the ETS (25). Four of the patients reported pain 
upon movement, although the pain was less severe than it had been prior to surgery 
(25). All patients reported improvements in quality of life (25). Follow-up studies 
cited in the literature by Perez et al. (18) determined that pain relief due to surgical 
sympathectomy declined over time and that patients who received the surgery 
within three months of the initial inciting event exhibited the most favorable 
prognosis.  
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Both physical therapy (PT) and occupational therapy (OT) are increasingly 
common treatment interventions for patients with CRPS and are typically given in 
conjunction with medications (18). A study by Oerlemans et al. (26) compared the 
efficacy of both PT and OT in the treatment of CRPS, assessing a cohort of 135 
patients with upper-limb CRPS of less than one year’s duration. These patients were 
assigned to a group receiving PT, a group receiving OT, or a control group (26). 
Pain was measured prior to the initiation of treatment using a visual analog scale 
and the McGill Pain Questionaire (MPQ) and was reassessed after six weeks, three 
months, six months, and twelve months (26). ROM was also assessed regularly 
(26). At the conclusion of twelve months, patients who had undergone PT—and, to 
a lesser extent, OT—reported greater improvements in visual analog pain scores 
and less pain on the MPQ than did patients in the control group (26). ROM of the 
upper distal extremities also improved with PT and, to a lesser extent, OT (26). It 
is evident that both pain and ROM can be significantly improved by PT and OT in 
patients with upper-limb CRPS. PT and OT have also increasingly become part of 
the standard course of treatment in patients with CRPS (18). Limited research exists 
on the benefits of these therapies in patients with chronic CRPS, however, and no 
studies exist regarding the efficacy of OT and PT in patients with lower-limb CRPS 
(18). 
Prognosis 
The prognosis for CRPS patients is variable and uncertain. The most 
reliable prognostic factor is timing of diagnosis and initiation of treatment. As 
previously stated, the earlier the condition is diagnosed and treated, the more 
favorable the prognosis. Studies indicate that some patients with CRPS experience 
spontaneous remission of symptoms, and in some cases, remission is permanent 
(28). More commonly, however, patients experience only partial remission, in 
which signs of CRPS linger (28). Even among patients who experience spontaneous 
complete remission in symptoms, relapse can occur (28).  
Studies are mixed with regard to the prognosis for patients diagnosed with 
CRPS during childhood and adolescence. Some studies have found that patients 
with CRPS diagnosed during childhood have more favorable outcomes than do 
those diagnosed as adults. Other studies have found no significant difference in 
prognosis for childhood-onset versus adult-onset CRPS. A study by Wilder et al. 
(29) conducted primary and follow-up assessments of 70 adolescents (mean age of 
12.5 years) with CRPS. It was found that younger patients experienced less-severe 
CRPS symptoms and more-favorable prognoses than did older patients (28, 29). 
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Additionally, upon follow-up, younger patients exhibited a shorter duration of 
deleterious symptoms related to CRPS (28, 29).  
Several studies contradict the findings of Wilder and colleagues, however. 
In a study by Tan et al. (30), a quality-of-life survey was given to 42 adults who 
had been treated for childhood-onset CRPS-1. The average time between childhood 
diagnosis and survey response was 12 years (30). More than half of the patients 
reported pain at the time of follow-up, and many of the typical signs and symptoms 
of CRPS had remained unchanged through the course of the disease (30). Fifteen 
patients also reported relapse in symptoms (30). These findings suggest that 
children with CRPS may have a less-favorable prognosis than earlier studies have 
indicated.   
The implications of these latter studies for young people diagnosed with 
CRPS are extremely dire. The direct and secondary effects of living with chronic 
pain, taking medications that carry serious side effects and risk of dependency, 
depression, and other secondary health conditions such as overuse injuries are 
likely compounded over the course of a lifetime; thus, early diagnosis and initiation 
of treatment in children with CRPS is paramount for the preservation of long-term 
quality of life and well-being.  
Secondary Health Conditions 
CRPS can lead to debilitating secondary conditions that profoundly affect 
quality of life. Several common secondary conditions related to CRPS include 
depression, anxiety, sleep disturbances, drug dependency, and overuse injuries in 
non-affected extremities (15). These secondary conditions are certainly not unique 
to CRPS, as they are commonly seen in a variety of chronic pain conditions.  
Interestingly, secondary conditions were prominent in both patients profiled 
in the case studies in this paper. Patient 1, who was diagnosed with CRPS more 
than three years after the initial inciting trauma, has reported significant life-altering 
secondary conditions as a result of her chronic CRPS. Patient 1 is moderately 
depressed and unable to carry out previously simple activities of daily living (such 
as holding her children) and has reported severe pain in the non-affected extremity 
because of overuse. She also reports widespread allodynia. These physical and 
psychological symptoms, combined with her inability to perform customary 
household activities, have strained her marriage significantly.  
Patient 2 does not have to juggle a career and raising young children like 
Patient 1 does; nevertheless, she reports significant secondary conditions related to 
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her CRPS. These include moderate depression and overuse injury in her non-
affected extremity.   
Case Studies 
Patient 1 
Patient 1 is a 30-year-old female. She experienced a household accident on 
Christmas morning of 2016 and was seen at the emergency department of a local 
rural community hospital for a laceration of the extensor tendon in the left ring 
finger. She also experienced numbness and tingling in the lacerated finger. She met 
with a hand surgeon the following day. Upon physical examination, there was no 
active flexion at the flexor digitorum profundus (FDP) joint or ability to flex the tip 
of the finger. The surgeon suspected a ruptured FDP tendon and promptly 
recommended surgery. An exploration of the left ring finger was performed on 
December 30, and it was found that the FDP tendon and the ulnar digital nerve were 
significantly damaged. The FDP tendon and ulnar digital nerve were then repaired, 
and an Axogen nerve guard was implanted. This patient sustained two distinct, 
significant insults to the ulnar digital nerve: the initial laceration, followed by the 
surgical repair; this patient’s CRPS would therefore be categorized as CRPS-2.   
Several months after the initial surgery, Patient 1 continued to report 
significant pain in the left ring finger. The injury had already affected her 
employment status, and she needed regular PT. She also began to develop tendinitis 
in the right wrist from overuse. After careful examination of the finger by a second 
surgeon, Patient 1 was diagnosed with an ulnar digital nerve neuroma. Surgery was 
performed in order to remove the neuroma. Importantly, following this second 
surgery Patient 1 began to develop pain in the left shoulder and neck area, as well 
as skin temperature changes. Her doctors believed that this pain was mechanical in 
nature, perhaps due to an intraoperative traction injury. For the next three years, the 
patient’s symptoms persisted and gradually worsened. Over time, the left finger 
pain traveled up the entire left arm with a cold sensation. A “sunburn” type 
sensation in the left arm, accompanied by hyperalgesia, was also noted. In the fall 
of 2019, Patient 1 was diagnosed with CRPS-2 in the left upper extremity. 
CRPS has affected every aspect of this patient’s life. She is a nurse and 
worked 38–42-hour weeks prior to the injury to her left finger. Following the initial 
injury, she was out of work for roughly five months. Since that time, she has been 
able to work only part time, as the left-hand and arm pain from CRPS have become 
almost unbearable. This has affected her family’s finances. Her doctors have 
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recommended regular ketamine infusion therapy, but this treatment is not covered 
under her health insurance, and her limited work schedule has made it impossible 
for her to pay for the ketamine infusions out of pocket.  
Patient 1 is married and has two children. Since the initial injury and onset 
of CRPS, the simple action of holding her children has become impossible. This 
has greatly affected her marriage and her ability to care for her children. These life-
altering events have led to a diagnosis of depression (a common secondary 
condition of CRPS) in this patient.  
Below is a list of Patient 1’s current CRPS symptoms. 
• Shoulder and neck pain following surgery 
• Shooting pain from left ring finger to left side of neck 
• Hypersensitivity of left ring finger (spread to other areas of the body) 
• Cold skin on left hand and arm 
• Temperature changes 
• Color changes in left hand and arm 
• Edema 
• Numbness in left hand 
• “Sunburn” type sensation throughout entire left upper extremity 
• Abnormal sensations 
• Plastic appearance of left hand compared to right hand 
• Sleep disturbances due to pain in left upper extremity  
• Trophic changes on left hand 
• Cyanotic appearance of left upper extremity  
Patient 2 
Patient 2 is a 64-year-old female. She suffered a fall in February of 2017 
while walking on a sidewalk with uneven pavement. She landed on her outstretched 
right arm and felt immediate severe pain in her right upper arm. She was taken to a 
local emergency department via ambulance. X-rays revealed a fracture of the right 
proximal humerus involving the surgical neck and greater tubercle. She was 
discharged with a sling and was told to follow up with the orthopedic doctor of her 
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choice. She did so, the fracture healed routinely, and she did well on the prescribed 
pain medications; however, in May of 2017, she began to develop pain and 
numbness in her right hand and fingers. She also had extreme grip difficulties. Her 
treating physician suspected CRPS and ordered a TPBS. The TPBS showed 
increased blood flow with soft-tissue inflammation and osseous uptake in the 
periarticular regions of the right upper extremity consistent with CRPS. This 
confirmed the treating orthopedist’s clinical diagnosis of CRPS. A second opinion 
also confirmed the CRPS diagnosis.  
Since the time of her diagnosis, Patient 2 has reported referred pain in her 
neck and in her left (uninjured) arm. She has been prescribed gabapentin, tramadol, 
and ibuprofen and has been participating in regular PT. Unfortunately, these 
therapies have not resolved her severe pain. Her doctors have recommended that 
she undergo a stellate ganglion block, but Patient 2 has a severe phobia of needles 
because of complications that her mother suffered during a medical procedure years 
ago. In the spring of 2020, Patient 2 had decided to go forward with the injection 
therapy despite her phobia, because the pain had become unbearable, but the 
procedure was canceled because of the COVID-19 pandemic, and at the time of 
this writing, she was in the process of rescheduling her injection.  
Below is a list of Patient 2’s current symptoms. 
• Right-hand pain, swelling, and numbness 
• Right-hand hyperhidrosis 
• Tingling in right hand and arm 
• Sensitivity to cold weather 
• Feeling of intense cold in right hand  
• Skin-color changes in right hand 
• Trophic changes in right hand 
• Sleep disturbances due to pain in right upper extremity  
• Allodynia in right hand and arm 
• Decreased motor function in right hand and arm 
Patient 2 presents an interesting case, in that she was diagnosed with CRPS 
early, within several months of the inciting trauma. Because of her phobia of 
needles and resulting apprehension toward the evidence-based stellate ganglion 
block therapy, however, she has been unable to avail herself of the most promising 
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therapies for her condition. It remains to be seen if the injections that will be done 
roughly three years after diagnosis will be effective.  
Both case studies featured above demonstrate the real-life barriers that 
individuals experience when attempting to receive the best, most effective 
treatment for the management of CRPS.  
Conclusion 
CRPS is a fascinating yet challenging condition for medical professionals. 
Accurate, timely diagnosis and effective treatment can be elusive with even the 
most experienced and conscientious physicians. Patients suffering from CRPS live 
with persistent severe pain, and this can affect every aspect of their lives, including 
career, family life, mental health, and overall quality of life. Additional research on 
CRPS is therefore vitally important and will, hopefully, lead to improvements in 
the diagnosis, treatments, and outcomes for patients with the condition. 
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